The Glivec patent expires in most countries latest on 21 Dec 2016.

The CML Advocates Network has been following the situation of TKI generics closely for 3 years, and has now provided a webinar which summarizes the current status.

This webinar answers some important questions, such as:

  • What are generics, and do they differentiate from innovator products?
  • Which generics of CML Tyrosine Kinase Inhibitors exist?
  • What do we know about efficacy and safety?
  • What information on CML generics is available to patients?
  • What has the patient advocacy community done so far?
  • What can patients and patient advocacy groups do about CML generics?

More can be found on our CML Advocates Network Knowledge Base on CML Generics at

If you want access to the slides, please contact Jan Geissler at .

Webstream via AuthorStream (allows to skip slides)










Olga Lucia Jimenez Community Builder Avatar   15.12.2016 (12:20:48)
Generic drugs for cml Yes No Would like to have access to the webinar

Please donate!

Please donate!


Tweet Feed

@WECANadvocate Thank you so much, @WECANadvocate! The aim is to provide #CML patients and HCPs with more evidence w……

Monday, 19 March 2018 in reply to WECANadvocate

One of our members, @cmlnet is running a survey to find out what the patient experience is on……

Retweeted Monday, 19 March 2018

Have you taken the #TFR4CML survey yet? If not, the weekend is a good moment to dedicate 20 minutes to this questio……

Saturday, 17 March 2018